» Articles » PMID: 12207972

Neurobiology of Ammonia

Overview
Journal Prog Neurobiol
Specialty Neurology
Date 2002 Sep 5
PMID 12207972
Citations 170
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperammonemia resulting from inherited urea cycle enzyme deficiencies or liver failure results in severe central nervous system dysfunction including brain edema, convulsions and coma. Neuropathologic evaluation in these disorders reveals characteristic alterations of astrocyte morphology ranging from cell swelling (acute hyperammonemia) to Alzheimer Type II astrocytosis (chronic hyperammonemia). Having no effective urea cycle, brain relies on glutamine synthesis for the removal of excess ammonia and the enzyme responsible, glutamine synthetase, has a predominantly astrocytic localization. Accumulation of ammonia in brain results in a redistribution of cerebral blood flow and metabolism from cortical to sub-cortical structures. In addition to changes in astrocyte morphology, increased brain ammonia concentrations result in alterations in expression of key astrocyte proteins including glial fibrillary acidic protein, glutamate and glycine transporters and "peripheral-type" (mitochondrial) benzodiazepine receptors. Such changes result in alterations of astrocytic volume and increased extracellular concentrations of excitatory and inhibitory substances. In addition, the ammonium ion has direct effects on excitatory-inhibitory transmission via distinct mechanisms involving cellular chloride extrusion and postsynaptic receptor function. Acute ammonia exposure leads to activation of NMDA receptors and their signal transduction pathways. Chronic hyperammonemia also results in increased concentrations of neuroactive L-tryptophan metabolites including serotonin and quinolinic acid. Therapy in hyperammonemic syndromes continues to rely on ammonia-lowering strategies via peripheral mechanisms (reduction of ammonia production in the gastrointestinal tract, increased ammonia removal by muscle).

Citing Articles

The Glutamate/GABA-Glutamine Cycle: Insights, Updates, and Advances.

Andersen J J Neurochem. 2025; 169(3):e70029.

PMID: 40066661 PMC: 11894596. DOI: 10.1111/jnc.70029.


Ammonia and beyond - biomarkers of hepatic encephalopathy.

Gallego J, Ballester M, Fiorillo A, Casanova-Ferrer F, Lopez-Gramaje A, Urios A Metab Brain Dis. 2025; 40(1):100.

PMID: 39812958 PMC: 11735499. DOI: 10.1007/s11011-024-01512-7.


Investigating cognitive impairments and hippocampal proteome alterations in aged male rats with TAA-Induced minimal hepatic encephalopathy.

Singh V, Prasad S, Acharjee A, Srivastava S, Acharjee P Biogerontology. 2024; 26(1):30.

PMID: 39704865 DOI: 10.1007/s10522-024-10158-y.


Causal Links Between Renal Function and Cardiac Structure, Function, and Disease Risk.

Zhou X, Ruan W, Zhao L, Lin K, Li J, Liu H Glob Heart. 2024; 19(1):83.

PMID: 39524990 PMC: 11546326. DOI: 10.5334/gh.1366.


Modulation of brain energy metabolism in hepatic encephalopathy: impact of glucose metabolic dysfunction.

Prasad S, Acharjee A, Singh V, Trigun S, Acharjee P Metab Brain Dis. 2024; 39(8):1649-1665.

PMID: 39120853 DOI: 10.1007/s11011-024-01407-7.